Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein

British Journal of Cancer

Volumn 69, Issue 5, 1994, Pages 809-816

  Schlichtholz, B ^a   Tredaniel J ^b   Lubin, R ^a   Zalcman, G ^b   Hirsch, A ^b   Soussi, T ^a  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEIN P53;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MALE; PEPTIDE MAPPING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CARCINOMA, LARGE CELL; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DYSPNEA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMAN; LUNG DISEASES, OBSTRUCTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGE; PROTEIN P53; SUPPORT, NON-U.S. GOV'T;

EID: 0028273804     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.159     Document Type: Article

References (33)

1. BAINS, M.S. (1991). Surgical treatment of lung cancer. Chest, 100, 826–837.
2. BARTEK, J, BARTKOVA, J., VOJTESEK, B., STASKOVA, Z., LUKAS, J., REJTHAR, A., KOVARIK, J., MIDGLEY, C.A., GANNON, J.V. & LANE, D.P. (1991). Aberrant expression of the p53-oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6, 1699–1703.
3. BARTEK, J., BARTKOVA, J., LUKAS, J., STASKOVA, Z., VOJTESEK, B. & LANE, D.P. (1993). Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol., 169, 27–34.
4. BENCHIMOL, S., PIM, D. & CRAWFORD, L. (1982). Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J., 1, 1055–1062.
5. CARON DE FROMENTEL, C. & SOUSSI, T. (1992). TP53 Tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer, 4, 1–15.
6. CARON DE FROMENTEL, C., MAY-LEVIN, F., MOURIESSE, H., LEMERLE, J., CHANDRASEKARAN, K. & MAY, P. (1987). Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39, 185–189.
7. CHIBA, I., TAKAHASHI, T., NAU, M.M., D’AMICO, D., CURIEL, D.T., MITSUDOMI, T., BUCHHAGEN, D.L., CARBON, D., PIANTADOSI, S., KOGA, H., REISSMAN, P.T., SLAMON, D.J., HOLEMS, E C. & MINNA, J.D. (1990). Mutations in the p53 gene are frequent in primary, resected non-small-cell lung cancer. Oncogene, 5, 1603–1610.
8. CRAWFORD, L.V., PIM, D C. & BULBROOK, R.D. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30, 403–408.
9. D’AMICO, D., CARBONE, D., MITSUDOMI, T., NAU, M., FEDORKO, J., RUSSELL, E., JOHNSON, B., BUCHHAGEN, D., BODNER, S., PHELPS, R., GAZDAR, A. & MINNA, J.D. (1992). High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7, 339–346.
10. DAVIDOFF, A.M., IGLEHART, J.D. & MARKS, J R. (1992). Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl Acad. Sci. USA, 89, 3439–3442.
11. GEYSEN, H.M., MELOEN, R.H. & BARTELING, S.J. (1984). Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl Acad. Sci. USA, 81, 3998–4002.
12. GILLET, D., DUCANCEL, F., PRADEL, E., LÉONETTI, M., MÉNEZ, A. & BOULAIN, J.C. (1992). Insertion of a disulfide-containing neurotoxin into E. coli alkaline phosphatase: the hybrid protein retains both biological activities. Protein Eng., 5, 273–278.
13. HALL, P.A., RAY, A., LEMOINE, N.R., MIDGLEY, C.A., KRAUSZ, T. & LANE, D.P. (1991). p53 Immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet, 338, 513.
14. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. & HARRIS, C.C. (1991). p53 mutations in human cancers. Science, 253, 49–53.
15. IHDE, D.C. (1993). Chemotherapy of lung cancer. N. Engl. J. Med., 327, 1434–1441.
16. KISHIMOTO, Y., MURAKAMI, Y., SHIRAISHI, M., HAYASHI, K. & SEKIYA, T. (1992). Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52, 4799–4804.
17. LABRECQUE, S., NAOR, N., THOMSON, D. & MATLASHEWSKY, G. (1993). Analysis of the anti-p53 antibody response in cancer patients. Cancer Res., 53, 3468–3471.
18. LEGROS, Y., LACABANNE, V., D’AGAY, M., LARSEN, C., PLA, M. & SOUSSI, T. (1993). Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull, du Cancer, 80, 102–110.
19. MALKIN, D., LI, F.P., STRONG, L.C., FRAUMENI, J.F., NELSON, C.E., KIM, D.H., KASSEL, J., GRYKA, M.A., BISCHOFF, F.Z., TAINSKY, M.A. & FRIEND, S.H. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233–1238.
20. MITSUDOMI, T., STEINBERG, S.M., NAU, M.M., CARBONE, D., DAMICO, D., BODNER, S., OIE, H.K., LINNOILA, R.I., MULSHINE, J.L., MINNA, J.D. & GAZDAR, A.F. (1992). p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7, 171–180.
21. SAMESHIMA, Y., MATSUNO, Y., HIROHASHI, S., SHIMOSATO, Y., MIZOGUCHI, H., SUGIMURA, T., TERADA, M. & YOKOTA, J. (1992). Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene, 7, 451–457.
22. SCHAAKE-KONING, C., VAN DER BOGAERT, W., DALESIO, O., FESTEN, F., HOOGHENOUT, J., VAN HOUTTE, P., KIRKPATRICK, A., KOOLEN, M., MAAT, B., NIJS, A., RENAUD, A., RODRIGUS, P., SCHUSTER-UITTERHOEVE, L., SCULIER, J.P., VAN ZANDWIJK, N. & BARTELINK, H. (1992). Effect of concomitant cisplatin and radiotherapy on inoperable non small cell cancer. N. Engl. J. Med., 326, 524–530.
23. SCHLICHTHOLZ, B., LEGROS, Y., GILLET, D., GAILLARD, C., MARTY, M., LANE, D., CALVO, F. & SOUSSI, T. (1992). The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52, 6380–6384.
24. SOUSSI, T., CARON DE FROMENTEL, C., STORZBECHER, H.W., ULLRICH, S., JENKINS, J. & MAY, P. (1989). Evolutionary conservation of the biochemical properties of p53 -specific interaction of xenopus-laevis p53 with simian virus 40 large T-antigen and mammalian heat shock proteins-70. J. Virol., 63, 3894–3901.
25. SOUSSI, T., CARON DE FROMENTEL, C. & MAY, P. (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5, 945–952.
26. SRIVASTAVA, S., ZOU, Z.Q., PIROLLO, K., BLATTNER, W. & CHANGE, E.H. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature, 348, 747–749.
27. SUNDARESAN, V., GANLY, P., HASLETON, P., RUDD, R., SINHA, G., BLEEHEN, N.M. & RABBITS, P. (1992). p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene, 7, 1989–1997.
28. SUZUKI, H., TAKAHASHI, T, KUROISHI, T., SUYAMA, M., ARIYOSHI, Y., TAKAHASHI, T. & UEDA, R. (1992). p53 mutations in non-small-cell lung cancer in Japan -association between mutations and smoking. Cancer Res., 52, 734–736.
29. TAKAHASHI, T., NAU, M.M., CHIBA, I., BIRRER, M.J., ROSENBERG, R.K., VINOCOUR, M., LEVITT, M., PASS, H., GAZDAR, A.F. & MINNA, J.D. (1989). p53 -a frequent target for genetic abnormalities in lung cancer. Science, 246, 491–494.
30. TAKAHASHI, T., TAKAHASHI, T., SUZUKI, H., HIDA, T., SEKIDO, Y., ARIYOSHI, Y. & UEDA, R. (1991). The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6, 1775–1778.
31. VOJTESEK, B., BARTEK, J., MIDGLEY, C.A. & LANE, D.P. (1992). An immunochemical analysis of the human nuclear phosphoprotein-p53 -new monoclonal antibodies and epitope mapping using recombinant-p53. J. Immunol. Methods, 151, 237–244.
32. WADE-EVANS, A. & JENKINS, J.R. (1985). Precise epitope mapping of the murine transformation-associated protein. p53. EMBO J., 46, 575–583.
33. WINTER, S.F., MINNA, J.D., JOHNSON, B.E., TAKAHASHI, T., GAZDAR, A.F. & CARBONE, D.P. (1992). Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res., 52, 4168–4174.